InterMune Inc. on Thursday will launch the first drug approved in Europe for use against a fatal lung-scarring disease.
The Brisbane company (NASDAQ: ITMN), which has struggled to win approval in the United States for Esbriet for patients with idiopathic pulmonary fibrosis, or IPF, will make the drug commercially available initially in Germany.
No comments:
Post a Comment